Comparison · NCT05223920-sae
Essential Thrombocythemia (ET) vs Myelofibrosis (MF): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Essential Thrombocythemia (ET) vs Myelofibrosis (MF): serious adverse events. Trial comparisons, record NCT05223920-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05223920-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.365 | 0.248 | 0.501 | wilson | |
| Risk in group 2 | 0.414 | 0.255 | 0.593 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0484 | -0.262 | 0.16 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.883 | 0.503 | 1.55 | log | |
| Odds ratio, group 1 over group 2 | 0.816 | 0.322 | 2.07 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Essential Thrombocythemia (ET) than on Myelofibrosis (MF) | 20.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Essential Thrombocythemia (ET) | Participants with ET received bomedemstat daily as an oral capsule. The daily dose of bomedemstat was titrated for each participant to a dose that reduced platelets to the target range associated with the participant's underlying MPN. | 19 | 52 | EG000 |
| Group 2 | Myelofibrosis (MF) | Participants with MF received bomedemstat daily as an oral capsule. The daily dose of bomedemstat was titrated for each participant to a dose that reduced platelets to the target range associated with the participant's underlying MPN. | 12 | 29 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Death and adverse events up to ~32 months
Source ClinicalTrials.gov
Trial
- Title
- An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)
- NCT number
- NCT05223920
- Phases
- PHASE2
- Conditions
- Thrombocythemia, Essential, Primary Myelofibrosis
- Interventions
- Bomedemstat
- Lead sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Results first posted
- 2025-09-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05223920?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05223920-sae